Researchers develop potential vaccine against antibiotic-resistant enterococci medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies of its vaccine candidates against Marburg virus and Sudan virus. The data were presented during the World Vaccine Congress, West Coast conference, bein
"This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices," Annaliesa Anderson, Pfizer's head of vaccine research and development, said in a statement. In the trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' updated COVID-19 vaccine given at the same visit.
SCHLIEREN, Switzerland, October 09, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr
BioNTech would initiate an early-to-mid stage trial for the vaccine program BNT166 to prevent mpox, a viral illness that causes skin rashes and could be transmitted to humans through physical contact. The vaccine candidates are based on the same messenger-RNA (mRNA) technology which has been used in its COVID shots developed with partner Pfizer. The partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) also aims to contribute to its mission to accelerate development of vaccines to be ready for regulatory authorization and manufacturing at scale within 100 days of recognition of pathogen with pandemic potential.